Clinical Trials | March 03, 2026
Merck’s KEYTRUDA & WELIREG combo shows breakthrough results in kidney cancer trial
Merck emphasized the broader significance of the findings
Merck emphasized the broader significance of the findings
Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
Lupin attained a score of 91 out of 100, establishing itself as the leading pharmaceutical company globally
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform
The innovative eyedrop targets inflammation and pain following ocular surgery
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
The MoU lays the groundwork for deep academic and research collaboration in pharmaceutical technologies
Subscribe To Our Newsletter & Stay Updated
